Poxel S.A. (POXEL.PA)
EUR 0.38
(-4.88%)
EUR 0.38
(-4.88%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 40.14 Million EUR | 59.18% |
| 2022 | 25.21 Million EUR | -16.2% |
| 2021 | 30.09 Million EUR | 43.41% |
| 2020 | 20.98 Million EUR | 1078.93% |
| 2019 | 1.78 Million EUR | 395.82% |
| 2018 | 359 Thousand EUR | -35.34% |
| 2017 | 555.21 Thousand EUR | -21.65% |
| 2016 | 708.59 Thousand EUR | -18.65% |
| 2015 | 871.08 Thousand EUR | -72.31% |
| 2014 | 3.14 Million EUR | 332.79% |
| 2013 | 726.92 Thousand EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 38.73 Million EUR | 0.0% |
| 2023 FY | - EUR | -100.0% |
| 2023 Q4 | 40.14 Million EUR | 0.0% |
| 2022 Q2 | 26.15 Million EUR | 0.0% |
| 2022 Q4 | 25.21 Million EUR | 0.0% |
| 2022 FY | 25.21 Million EUR | -16.2% |
| 2021 FY | 30.09 Million EUR | 43.41% |
| 2021 Q4 | 30.09 Million EUR | 0.0% |
| 2021 Q2 | 32.9 Million EUR | 0.0% |
| 2020 Q4 | 20.98 Million EUR | 0.0% |
| 2020 FY | 20.98 Million EUR | 1078.93% |
| 2020 Q2 | 16.75 Million EUR | 0.0% |
| 2019 Q2 | 1.33 Million EUR | 0.0% |
| 2019 Q4 | 1.78 Million EUR | 0.0% |
| 2019 FY | 1.78 Million EUR | 395.82% |
| 2018 Q2 | 470.86 Thousand EUR | 0.0% |
| 2018 FY | 359 Thousand EUR | -35.34% |
| 2018 Q4 | 359 Thousand EUR | 0.0% |
| 2017 Q2 | 641.24 Thousand EUR | 0.0% |
| 2017 FY | 555.21 Thousand EUR | -21.65% |
| 2017 Q4 | 555 Thousand EUR | 0.0% |
| 2016 Q2 | 638.21 Thousand EUR | 0.0% |
| 2016 FY | 708.59 Thousand EUR | -18.65% |
| 2016 Q4 | 708.59 Thousand EUR | 0.0% |
| 2015 FY | 871.08 Thousand EUR | -72.31% |
| 2015 Q2 | 2.06 Million EUR | 0.0% |
| 2015 Q4 | 871.08 Thousand EUR | 0.0% |
| 2014 Q2 | 725.81 Thousand EUR | 0.0% |
| 2014 Q4 | 3.14 Million EUR | 0.0% |
| 2014 FY | 3.14 Million EUR | 332.79% |
| 2013 Q4 | 726.92 Thousand EUR | 0.0% |
| 2013 FY | 726.92 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -3546.049% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 10.189% |
| Adocia SA | 4.54 Million EUR | -784.207% |
| Aelis Farma SA | 2.04 Million EUR | -1860.107% |
| Biophytis S.A. | 3.11 Million EUR | -1190.357% |
| Advicenne S.A. | 15.89 Million EUR | -152.535% |
| genOway Société anonyme | 5.51 Million EUR | -627.32% |
| IntegraGen SA | 642.28 Thousand EUR | -6150.078% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3245.25% |
| Neovacs S.A. | 650 Thousand EUR | -6075.846% |
| NFL Biosciences SA | 39.2 Thousand EUR | -102297.776% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -821.449% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -1947.769% |
| Sensorion SA | 1.24 Million EUR | -3134.962% |
| Theranexus Société Anonyme | 2.46 Million EUR | -1531.353% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -929.836% |
| TheraVet SA | 1 Million EUR | -3911.897% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -481.277% |
| DBV Technologies S.A. | 4.52 Million USD | -786.942% |
| Genfit S.A. | 62.25 Million EUR | 35.516% |
| GeNeuro SA | 6.49 Million EUR | -518.317% |
| Innate Pharma S.A. | 30.6 Million EUR | -31.156% |
| Inventiva S.A. | 25.61 Million EUR | -56.711% |
| MaaT Pharma SA | 5.42 Million EUR | -639.963% |
| MedinCell S.A. | 52.8 Million EUR | 23.972% |
| Nanobiotix S.A. | 41.66 Million EUR | 3.641% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -13.053% |
| GenSight Biologics S.A. | 1.04 Million EUR | -3730.439% |
| Transgene SA | 17 Thousand EUR | -236035.294% |
| Valneva SE | 132.76 Million EUR | 69.765% |